Evid Invest

AKTX vs BMYMP: Valuation Comparison 2026

Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings.

Side-by-side fundamentals for Akari Therapeutics Plc (AKTX) and Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) — market cap, PE, PEG and sector. All figures from SEC filings and market data.

Akari Therapeutics Plc

AKTX

Healthcare

Full AKTX valuation →

Bristol-Myers Squibb Company PFD CONV 2

BMYMP

Healthcare

Full BMYMP valuation →
MetricAKTXBMYMP
SectorHealthcareHealthcare
IndustryBiotechnologyDrug Manufacturers - General
Current Price (Cboe, delayed)$9.01$400
Market Cap$1.40T$814.59B
PE Ratio—87.91
PEG Ratio—16.51
PEG VerdictN/APotentially Overvalued
AKTX fair valueBMYMP fair valueAKTX supply chainBMYMP supply chain

More comparisons

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.